9.75

2.21% -0.22

After Hours: 9.75

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $9.75, with a volume of 1.34M. It is down -2.21% in the last 24 hours and down -2.50% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$9.97

Open:

$10

24h Volume:

1.34M

Relative Volume:

0.85

Market Cap:

$3.06B

Revenue:

$2.68B

Net Income/Loss:

$-184.45M

P/E Ratio:

-14.33

EPS:

-0.6805

Net Cash Flow:

$229.23M

1W Performance:

-7.58%

1M Performance:

-2.50%

6M Performance:

+39.68%

1Y Performance:

+13.77%

1-Day Range:

$9.685

$10.09

1-Week Range:

$9.685

$10.62

52-Week Range:

$6.685

$10.68

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1142)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2025-05-02

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	9.75	3.13B	2.68B	-184.45M	229.23M	-0.6805
ZTS Zoetis Inc	142.26	62.54B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.72	43.30B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.08	40.08B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	20.02	22.98B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	440.06	19.90B	3.08B	1.24B	1.07B	25.61

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-06-25	Initiated	Goldman	Buy
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

11:29 AM

What MACD and RSI say about Amneal Pharmaceuticals Inc.Trade Analysis Summary & Community Verified Swing Trade Signals - newser.com

11:29 AM

05:37 AM

Will Amneal Pharmaceuticals Inc. stock benefit from automationIPO Watch & Accurate Entry and Exit Point Alerts - newser.com

05:37 AM

Oct 12, 2025

Amneal Pharmaceuticals Hits New 52-Week High of $10.67 - Markets Mojo

Oct 12, 2025

Oct 11, 2025

FDA grants tentative approval for Amneal generic of Bausch Health's Xiafan - MSN

Oct 11, 2025

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 11, 2025

Oct 10, 2025

Will Amneal Pharmaceuticals Inc. see short term momentumTrade Analysis Report & Daily Volume Surge Signals - newser.com

Oct 10, 2025

Why Amneal Pharmaceuticals Inc. stock is considered a top pick2025 Market Outlook & Smart Swing Trading Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Benzinga

Oct 09, 2025

Will Amneal Pharmaceuticals Inc. price bounce be sustainable2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com

Oct 09, 2025

When is the best time to exit Amneal Pharmaceuticals Inc.July 2025 Outlook & Weekly High Return Stock Opportunities - newser.com

Oct 09, 2025

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Biosimilar XOLAIR FDA Submission – Learn Why - Yahoo Finance

Oct 09, 2025

Technical analysis overview for Amneal Pharmaceuticals Inc. stockEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com

Oct 09, 2025

Oct 08, 2025

A Look at Amneal Pharmaceuticals’s Valuation After XOLAIR Biosimilar Submissions and Recent Analyst Upgrades - Yahoo Finance

Oct 08, 2025

Amneal Pharmaceuticals (NASDAQ:AMRX) Receives Hold (C) Rating from Weiss Ratings - MarketBeat

Oct 08, 2025